Leukopaks are the result of a cell concentration process starting from healthy and consenting donors’ blood (Leukapheresis) according to an IRB-approved protocol.

Leukopaks can be used as a starting material for the isolation of specific immune cell types to be cryopreserved and employed for the discovery of Small and Large molecules, as well as as Vaccines and Cell and Gene Therapies; alternatively, they can be used as a starting material for process development.

The concentration of leukocytes in Leukapheresis is higher than in whole blood, and the concentration of mononuclear cells (MNCs) is higher than in buffy coats (typical concentration up to 20% monocytes, 50% T-Cells, 10% B-Cells, 10% Natural Killer cells, 3% granulocytes).


Isolating individual cell types from Leukopaks allows to achieve high cell yields and reduce the donor-dependent variability between experiments. It is nonetheless important to consider that individual donor characteristics such as age, height, gender, BMI, smoking habits or a particular clinical history can result in variability in assay performance and in the proportion between the cellular components. Increasing donor variability in your studies can improve process robustness in the latest development stages and even gain important insights in outliers.

If you are interested to integrate more donor variability in your safety studies:


PBMC Samples
Remnant Lab Samples
Characterized FFPE Blocks
This site is registered on wpml.org as a development site.